Formycon AG FYB.DE · Stock Open Formycon AG in new tab
Formycon AG Analysis (FYB.DE)
Is Formycon AG a good investment? Formycon AG (FYB.DE) is currently trading at 18.60 EUR. Market analysts have a consensus price target of 39.67 EUR. This suggests a potential upside from current levels.
Earnings Schedule: Formycon AG is expected to release its next earnings report on April 29, 2027. The market consensus estimate for Forward EPS is 1.11.
Investor FAQ
Does Formycon AG pay a dividend?
No, it does not currently pay a dividend.
What asset class is Formycon AG?
Formycon AG is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be April 29, 2027. The company currently has a trailing EPS of -3.66.
Company Profile
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, asthma, hodgkin's lymphoma, urothelial carcinomas, tumors in the head and neck area, sinusitis with nasal polyps area, other tumor and genetic diseases; and FYB208 and FYB209 that is indicated for immunology areas. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Community Discussion